IL10RB and metastatic melanoma: Further analysis of the transcriptomic data and the anti–PD-1 therapy response in a cohort of 30 patients with metastatic melanoma (38) revealed that tumors with higher IL10RB-DT expression are resistant to anti–PD-1 treatment (Fig. 2F).